Advanced Oncotherapy #AVO – Dr Enrico Vanni director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company purchased 40,000 ordinary shares of 25 pence in the Company at a price of 54.5 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,263,946 Ordinary Shares, representing 1.56% of the […]

Advanced Oncotherapy (AVO) – Director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company, purchased 100,000 ordinary shares of 25 pence in the Company at a price of 17.75 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,223,946 Ordinary Shares, representing 1.51% of the […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company at a price of 26.96 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,123,946 Ordinary Shares, representing 1.52% of the issued share […]

Advanced Oncotherapy (AVO) – Director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company at a price of 27.5 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,023,946 Ordinary Shares, representing 1.40% of the issued share […]

Advanced Oncotherapy (AVO) – Additional director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the notification earlier today Dr Enrico Vanni, Non-Executive Director, has today purchased a further 25,000 ordinary shares of 25 pence in the Company at a price of 29.25 pence per Ordinary Share.  Following this transaction, Dr Vanni […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday the Directors below purchased ordinary shares of 25 pence in the Company. Director No of Ordinary Shares purchased   Price paid Resultant shareholding   %  of the issued share capital Dr Michael Sinclair, Executive Chairman 100,000 28.35p 4,728,229 6.51% Dr […]

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 87 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 823,946 Ordinary Shares representing […]

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, has today purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 66 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 798,946 […]

Advanced Oncotherapy (AVO) – Additional director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 59.75 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 773,946 Ordinary Shares […]

Advanced Oncotherapy (AVO) – Additional Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, a Non-Executive Director of the Company, purchased 25,000 ordinary shares of 25 pence each in the Company at a price of 55 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 723,946 Ordinary […]